# Wan‐Teck Lim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wan-teck-lim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,184 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 47 |
| i10-index | 127 |
| Last Known Institution | National Cancer Centre Singapore |
| OpenAlex ID | https://openalex.org/A5035273217 |
| ORCID iD | 0000-0002-4655-0206 |
| Works | 500 |

## Researcher papers

- [Isolation and retrieval of circulating tumor cells using centrifugal forces](https://scholariq.org/papers/isolation-and-retrieval-of-circulating-tumor-cells-using-centrifugal-forces/)
- [A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer](https://scholariq.org/papers/a-common-bim-deletion-polymorphism-mediates-intrinsic-resistance-and-inferior/)
- [Genomic landscape of lung adenocarcinoma in East Asians](https://scholariq.org/papers/genomic-landscape-of-lung-adenocarcinoma-in-east-asians/)
- [Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)](https://scholariq.org/papers/antitumor-activity-of-nivolumab-in-recurrent-and-metastatic-nasopharyngeal/)
- [Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study](https://scholariq.org/papers/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in/)
- [Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity](https://scholariq.org/papers/never-smokers-with-lung-cancer-epidemiologic-evidence-of-a-distinct-disease/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)
- [Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma](https://scholariq.org/papers/toripalimab-plus-chemotherapy-for-recurrent-or-metastatic-nasopharyngeal/)
- [Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma](https://scholariq.org/papers/adoptive-t-cell-transfer-and-chemotherapy-in-the-first-line-treatment-of/)
- [Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma](https://scholariq.org/papers/concurrent-chemo-radiation-with-or-without-induction-gemcitabine-carboplatin-and/)
- [EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer](https://scholariq.org/papers/ep12-01-31-updated-first-line-osimertinib-in-asian-patients-with-advanced-egfr/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Researcher university

- [National Cancer Centre Singapore](https://scholariq.org/institutions/national-cancer-centre-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.